| Financial Highlights | Financial Review | | Management’s Report | Audit Committee’s Report | | Independent Auditors’ Report | Financial Statements | Notes to Financial Statements | | Directors, Committees, and Officers | | Corporate and Shareholder Information |	| Consolidated Income | | Consolidated Balance Sheet | | Consolidated Shareholder’s Equity | | Consolidated Cash Flows | | Segment Information | Geographic Data | | Quarterly Data | Financial Summary |

Consolidated Balance Sheet

Pfizer Inc and Subsidiary Companies   December 31  (millions, except per share data) 1997 1996 1995  Assets       Current Assets       Cash and cash equivalents $    877 $  1,150 $    403  Short-term investments 712 487 1,109  Accounts receivable, less allowance for doubtful accounts:       1997 — $51; 1996 — $58; 1995 — $61 2,527 2,252   2,024  Short-term loans 115 354 289  Inventories       Finished goods 677 617 564  Work in process 852 695 579  Raw materials and supplies 244 277 241  Total inventories 1,773 1,589 1,384  Prepaid expenses, taxes and other assets 816 636 943  Total current assets 6,820 6,468 6,152  Long-term loans and investments 1,340 1,163 545  Property, plant and equipment, less accumulated depreciation 4,137 3,850 3,473  Goodwill, less accumulated amortization:       1997 — $152; 1996 — $115; 1995 — $79 1,294 1,424 1,243  Other assets, deferred taxes and deferred charges 1,745 1,762 1,316  Total assets  $15,336 $14,667 $12,729  Liabilities and Shareholders’ Equity       Current Liabilities       Short-term borrowings, including current portion of long-term debt $ 2,255 $ 2,235 $ 2,036  Accounts payable 765 913 715  Income taxes payable 785 892 822  Accrued compensation and related items 477 436 421  Other current liabilities 1,023 1,164 1,193  Total current liabilities 5,305 5,640 5,187  Long-term debt 729 687 833  Postretirement benefit obligation other than pension plans 394 412 426  Deferred taxes on income 156 253 166  Other noncurrent liabilities 819 721 611  Total liabilities 7,403 7,713 7,223  Shareholders’ Equity       Preferred stock, without par value; 12 shares authorized, none issued — — —  Common stock, $.05 par value; 3,000 shares authorized;       issued: 1997 — 1,388; 1996 — 1,378; 1995 — 1,371 69 69 69  Additional paid-in capital 3,239 1,693 1,200  Retained earnings 9,349 8,017 6,859  Currency translation adjustment and other (85) 145 163  Employee benefit trusts (2,646) (1,488) (1,170)  Treasury stock, at cost:       1997 — 94; 1996 — 87; 1995 — 96 (1,993) (1,482) (1,615)  Total shareholders’ equity 7,933 6,954 5,506  Total liabilities and shareholders’ equity  $15,336 $14,667 $12,729  See Notes to Consolidated Financial Statements which are an integral part of these statements.

	Advisory Information for Investors
	Copyright © 1997, 1998 Pfizer Inc All rights reserved.